Market Cap 37.95M
Revenue (ttm) 4.01M
Net Income (ttm) -26.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -672.57%
Debt to Equity Ratio 0.00
Volume 114,800
Avg Vol 419,066
Day's Range N/A - N/A
Shares Out 15.12M
Stochastic %K 36%
Beta -0.64
Analysts Strong Sell
Price Target $18.00

Company Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 744 4400
Address:
20 Park Plaza, Suite 424, Boston, United States
BPler
BPler Sep. 11 at 5:54 AM
$CRVO Not financial advise, but in biotech ticker I always read "How did you even know before the news?" In this case good chance for pop within 3 weeks, because: In corporate biotech, companies highly unlikely present bad or negative primary data in a prestigious, highly competitive "Late-Breaking Oral Session" at a major medical conference like ISFTD. https://www.biospace.com/press-releases/cervomed-announces-initial-results-from-the-phase-2a-clinical-trial-of-neflamapimod-in-nonfluent-variant-primary-progressive-aphasia-nfvppa-have-been-accepted-as-a-late-breaking-oral-session-at-isftd-2026
0 · Reply
Adorno99
Adorno99 Sep. 10 at 10:26 PM
$CRVO They may just drop some spectacular news tomorrow! CRVO session scheduled for 10:55 am.
0 · Reply
Hugoooo
Hugoooo Sep. 10 at 11:31 AM
$CRVO CervoMed Announces Initial Results From the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (Nfvppa) Have Been Accepted as a Late-Breaking Oral Session at Isftd 2026
0 · Reply
BPler
BPler Sep. 9 at 4:52 PM
$CRVO 382 Mio. market cap would be a x10 multiple, a share price of 25 USD. A long time ago this would have been my most conservative PT for Phase 3. PS A bit surprised we didnt bleed out more, but borrow fees falling down close to 50% for the first time for months now ..
2 · Reply
Doki0926
Doki0926 Sep. 9 at 4:17 PM
$CRVO shit company idiots real joke big huge shit with the worst retarded corrupt incompetent idiots in the board!!! Shame on them and on their whole family!!!! Shit!!!💩💩💩💩💩
0 · Reply
Spindr88
Spindr88 Sep. 8 at 2:07 PM
$CRVO another red week and new lows to look forward to… so many trapped in this poorly managed piece of rat 💩 company. No more pumpers here, just people stuck in a terrible investment.
1 · Reply
Stu_padasso
Stu_padasso Sep. 8 at 1:57 PM
$CRVO going under two? Doesnt appear to be a bottom anymore.
1 · Reply
stemark
stemark Sep. 8 at 1:54 PM
$CRVO constant sorrow
0 · Reply
focafoca99
focafoca99 Sep. 8 at 11:55 AM
$CRVO presents at multiple September investor conferences, including Cantor Global Healthcare and H.C. Wainwright events. https://www.rapidticker.com/news/crvo-cervomed-to-participate-in-september-907fb0
0 · Reply
BPler
BPler Sep. 8 at 11:41 AM
$CRVO https://ir.cervomed.com/news-releases/news-release-details/cervomed-participate-september-investor-conferences
1 · Reply
Latest News on CRVO
CervoMed to Participate in September Investor Conferences

Sep 8, 2026, 7:30 AM EDT - 2 days ago

CervoMed to Participate in September Investor Conferences


CervoMed price target lowered to $7 from $9 at Roth Capital

2026-08-20T10:40:11.000Z - 21 days ago

CervoMed price target lowered to $7 from $9 at Roth Capital


CervoMed price target lowered to $18 from $27 at Canaccord

2026-08-10T11:05:44.000Z - 4 weeks ago

CervoMed price target lowered to $18 from $27 at Canaccord


CervoMed Quarterly report: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 4 weeks ago

CervoMed Quarterly report: Q2 2026


CervoMed Earnings release: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 4 weeks ago

CervoMed Earnings release: Q2 2026


CervoMed completes enrollment in neflamapimod study

2026-07-09T11:40:46.000Z - 2 months ago

CervoMed completes enrollment in neflamapimod study


CervoMed Registration statement: Registration filing

Jul 6, 2026, 8:00 AM EDT - 2 months ago

CervoMed Registration statement: Registration filing


CervoMed announces $10.5M private placement

2026-06-10T11:44:51.000Z - 3 months ago

CervoMed announces $10.5M private placement


CervoMed announces $10.5M private placement

2026-06-10T11:41:14.000Z - 3 months ago

CervoMed announces $10.5M private placement


CervoMed Slides: Corporate presentation

Jun 10, 2026, 7:00 AM EDT - 3 months ago

CervoMed Slides: Corporate presentation


CervoMed price target lowered to $9 from $11 at Roth Capital

2026-05-18T21:35:08.000Z - 3 months ago

CervoMed price target lowered to $9 from $11 at Roth Capital


CervoMed Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

CervoMed Quarterly report: Q1 2026


CervoMed Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

CervoMed Earnings release: Q1 2026


CervoMed Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

CervoMed Proxy statement: Proxy filing


CervoMed presents neflamapimod MRI data

2026-04-22T14:32:59.000Z - 4 months ago

CervoMed presents neflamapimod MRI data


CervoMed Transcript: The 38th Annual Roth Conference

Mar 23, 2026, 3:00 PM EDT - 5 months ago

CervoMed Transcript: The 38th Annual Roth Conference


CervoMed Slides: The 38th Annual Roth Conference

Mar 23, 2026, 3:00 PM EDT - 5 months ago

CervoMed Slides: The 38th Annual Roth Conference


CervoMed’s neflamapimod shows efficacy in dementia with DLB

2026-03-19T11:56:17.000Z - 5 months ago

CervoMed’s neflamapimod shows efficacy in dementia with DLB


CervoMed price target lowered to $11 from $19 at Roth Capital

2026-03-17T23:00:26.000Z - 5 months ago

CervoMed price target lowered to $11 from $19 at Roth Capital


CervoMed price target raised to $21 from $15 at Chardan

2026-03-17T22:25:46.000Z - 5 months ago

CervoMed price target raised to $21 from $15 at Chardan


CervoMed Earnings release: Q4 2025

Mar 17, 2026, 4:00 PM EDT - 5 months ago

CervoMed Earnings release: Q4 2025


CervoMed Annual report: Q4 2025

Mar 17, 2026, 4:00 PM EDT - 5 months ago

CervoMed Annual report: Q4 2025


CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024

2026-03-17T11:46:53.000Z - 5 months ago

CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024


CervoMed Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 5 months ago

CervoMed Slides: Corporate presentation


CervoMed completes Phase 1 volunteer study for neflamapimod

2026-03-04T12:41:24.000Z - 6 months ago

CervoMed completes Phase 1 volunteer study for neflamapimod


CervoMed initiated with an Overweight at Cantor Fitzgerald

2025-12-18T11:40:57.000Z - 8 months ago

CervoMed initiated with an Overweight at Cantor Fitzgerald


CervoMed’s neflamapimod shows efficacy in slowing dementia

2025-12-04T22:05:45.000Z - 9 months ago

CervoMed’s neflamapimod shows efficacy in slowing dementia


CervoMed Earnings release: Q3 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

CervoMed Earnings release: Q3 2025


CervoMed Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

CervoMed Quarterly report: Q3 2025


CervoMed Transcript: Emerging Growth Conference

Oct 22, 2025, 11:25 AM EDT - 10 months ago

CervoMed Transcript: Emerging Growth Conference


CervoMed to Present at the Emerging Growth Conference

Oct 20, 2025, 8:00 AM EDT - 10 months ago

CervoMed to Present at the Emerging Growth Conference


CervoMed to Participate in Upcoming Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 1 year ago

CervoMed to Participate in Upcoming Investor Conferences


CervoMed Earnings release: Q2 2025

Aug 8, 2025, 4:00 PM EDT - 1 year ago

CervoMed Earnings release: Q2 2025


CervoMed Quarterly report: Q2 2025

Aug 8, 2025, 4:00 PM EDT - 1 year ago

CervoMed Quarterly report: Q2 2025


CervoMed Transcript: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

CervoMed Transcript: Status Update


CervoMed Press release: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

CervoMed Press release: Status Update


CervoMed Slides: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

CervoMed Slides: Status Update


CervoMed Slides: Corporate Presentation

Jun 25, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Corporate Presentation


CervoMed Slides: Corporate Presentation

May 28, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Corporate Presentation


CervoMed Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

CervoMed Earnings release: Q1 2025


CervoMed Quarterly report: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

CervoMed Quarterly report: Q1 2025


CervoMed Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

CervoMed Proxy statement: Proxy Filing


CervoMed Slides: Investor Presentation

Apr 5, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Investor Presentation


CervoMed Earnings release: Q4 2024

Mar 18, 2025, 4:00 PM EDT - 1 year ago

CervoMed Earnings release: Q4 2024


CervoMed Annual report: Q4 2024

Mar 18, 2025, 4:00 PM EDT - 1 year ago

CervoMed Annual report: Q4 2024


CervoMed Slides: Investor Presentation

Mar 11, 2025, 8:00 AM EDT - 1 year ago

CervoMed Slides: Investor Presentation


CervoMed Slides: Investor Presentation

Jan 31, 2025, 7:00 AM EST - 1 year ago

CervoMed Slides: Investor Presentation


CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals


CervoMed Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 3:00 PM EST - 1 year ago

CervoMed Transcript: Stifel 2024 Healthcare Conference


CervoMed Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Quarterly report: Q3 2024


CervoMed Registration statement: Registration Filing

Oct 3, 2024, 8:00 AM EDT - 1 year ago

CervoMed Registration statement: Registration Filing


CervoMed Quarterly report: Q2 2024

Aug 12, 2024, 4:00 PM EDT - 2 years ago

CervoMed Quarterly report: Q2 2024


CervoMed Earnings release: Q2 2024

Aug 12, 2024, 4:00 PM EDT - 2 years ago

CervoMed Earnings release: Q2 2024


CervoMed Transcript: Status Update

Jul 23, 2024, 10:00 AM EDT - 2 years ago

CervoMed Transcript: Status Update


CervoMed Slides: Corporate Presentation

Jul 22, 2024, 8:00 AM EDT - 2 years ago

CervoMed Slides: Corporate Presentation


CervoMed to Participate in the Emerging Growth Conference

Jul 17, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Participate in the Emerging Growth Conference


CervoMed Registration statement: Registration Filing

May 30, 2024, 8:00 AM EDT - 2 years ago

CervoMed Registration statement: Registration Filing


CervoMed to Appoint William Elder as Chief Financial Officer

May 20, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Appoint William Elder as Chief Financial Officer


BPler
BPler Sep. 11 at 5:54 AM
$CRVO Not financial advise, but in biotech ticker I always read "How did you even know before the news?" In this case good chance for pop within 3 weeks, because: In corporate biotech, companies highly unlikely present bad or negative primary data in a prestigious, highly competitive "Late-Breaking Oral Session" at a major medical conference like ISFTD. https://www.biospace.com/press-releases/cervomed-announces-initial-results-from-the-phase-2a-clinical-trial-of-neflamapimod-in-nonfluent-variant-primary-progressive-aphasia-nfvppa-have-been-accepted-as-a-late-breaking-oral-session-at-isftd-2026
0 · Reply
Adorno99
Adorno99 Sep. 10 at 10:26 PM
$CRVO They may just drop some spectacular news tomorrow! CRVO session scheduled for 10:55 am.
0 · Reply
Hugoooo
Hugoooo Sep. 10 at 11:31 AM
$CRVO CervoMed Announces Initial Results From the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (Nfvppa) Have Been Accepted as a Late-Breaking Oral Session at Isftd 2026
0 · Reply
BPler
BPler Sep. 9 at 4:52 PM
$CRVO 382 Mio. market cap would be a x10 multiple, a share price of 25 USD. A long time ago this would have been my most conservative PT for Phase 3. PS A bit surprised we didnt bleed out more, but borrow fees falling down close to 50% for the first time for months now ..
2 · Reply
Doki0926
Doki0926 Sep. 9 at 4:17 PM
$CRVO shit company idiots real joke big huge shit with the worst retarded corrupt incompetent idiots in the board!!! Shame on them and on their whole family!!!! Shit!!!💩💩💩💩💩
0 · Reply
Spindr88
Spindr88 Sep. 8 at 2:07 PM
$CRVO another red week and new lows to look forward to… so many trapped in this poorly managed piece of rat 💩 company. No more pumpers here, just people stuck in a terrible investment.
1 · Reply
Stu_padasso
Stu_padasso Sep. 8 at 1:57 PM
$CRVO going under two? Doesnt appear to be a bottom anymore.
1 · Reply
stemark
stemark Sep. 8 at 1:54 PM
$CRVO constant sorrow
0 · Reply
focafoca99
focafoca99 Sep. 8 at 11:55 AM
$CRVO presents at multiple September investor conferences, including Cantor Global Healthcare and H.C. Wainwright events. https://www.rapidticker.com/news/crvo-cervomed-to-participate-in-september-907fb0
0 · Reply
BPler
BPler Sep. 8 at 11:41 AM
$CRVO https://ir.cervomed.com/news-releases/news-release-details/cervomed-participate-september-investor-conferences
1 · Reply
Adorno99
Adorno99 Sep. 4 at 2:37 PM
$CRVO expecting good news right before the long weekend!
0 · Reply
David_M_
David_M_ Sep. 4 at 1:44 PM
0 · Reply
Mfv
Mfv Sep. 4 at 12:47 PM
$CRVO let's go management team!
0 · Reply
Spindr88
Spindr88 Sep. 3 at 7:47 PM
$CRVO yep still trash…
0 · Reply
walker7782
walker7782 Sep. 3 at 12:07 PM
$CRVO Still here, fall conference announcements are likely imminent. Institutional short positions need volume to cover. Will flip and load again for partnership news, probably Q1 2027. Just my $.02
1 · Reply
BPler
BPler Sep. 1 at 4:24 PM
Adding $UAA as my next undervalued add, while moving from $GPRO (where I started at 1.46 USD adding constantly with the dips to exit at 1.49 USD with an average of 0.79). If you spot an undervalued stock, you personally like their product and it is on unusual downtrend it is worth to take deeper look and make your own DD to start small and adding with the dips, rather chasing the highs. This tactic did me personally better than in the past were I was too late and needed to chase with big initial investments. Still adding at $CRVO and $EVH as well.
0 · Reply
CapSampler
CapSampler Sep. 1 at 5:32 AM
$CRVO could run to the moon on news.
1 · Reply
Spindr88
Spindr88 Sep. 1 at 12:47 AM
$CRVO wow a green day?! 🍿
0 · Reply
Mfv
Mfv Aug. 31 at 9:29 PM
$CRVO Big day!!!! .03 maybe a nickel tomorrow.
0 · Reply
Ghostofgreg1
Ghostofgreg1 Aug. 29 at 1:36 PM
$CRVO The only way to look at it now is that they have 90 days from here. 90 days to announce something spectacular 90 days to announce something that will make the now 6 year wait for some of us worth it 90 days to announce something that will be truly helpful for the community that suffers. 90 days The clock is now truly ticking.
3 · Reply
SteveO_TX_to_FL
SteveO_TX_to_FL Aug. 29 at 12:09 AM
$CRVO I don’t know who’s worse: shallow chearleaders or unreasonable doomsayers. It’s pretty close.
1 · Reply
K4mpas
K4mpas Aug. 28 at 4:56 PM
$CRVO at least you will enjoy
0 · Reply